Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Corp (SLXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Silexion Therapeutics Corp 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 ISR

www.silexion.com Employees: 0 P: 972-8628-6005

Description:

Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. Silexion Therapeutics Ltd., formerly known as Biomotion Sciences, is based in NEW YORK.

Key Statistics

Overview:

Market Capitalization, $K 4,606
Enterprise Value, $K 4,496
Shares Outstanding, K 13,828
Annual Sales, $ 0 K
Annual Net Income, $ 260 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -11,860 K
EBIT, $ -8,840 K
EBITDA, $ -8,840 K
60-Month Beta -0.11
% of Insider Shareholders 33.00%
% of Institutional Shareholders 10.95%
Float, K 9,265
% Float 67.00%
Short Volume Ratio 0.52

Growth:

1-Year Return -87.51%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.03 on 11/14/24
Next Earnings Date 12/05/24
Earnings Per Share ttm -7.90
EPS Growth vs. Prev Qtr 65.42%
EPS Growth vs. Prev Year 557.15%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SLXN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -249.43%
Profit Margin % 0.00%
Debt/Equity -0.89
Price/Sales N/A
Price/Cash Flow 3.33
Price/Book N/A
Book Value/Share -0.33
Interest Coverage -1.23
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar